Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Debora S. Bruno"'
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 686-694 (2024)
Introduction: Non-bacterial thrombotic endocarditis is well documented in the literature to occur in patients with known malignancies. It is, however, much less common for patients to be diagnosed with marantic endocarditis as the presenting sign of
Externí odkaz:
https://doaj.org/article/963b2d1205a0461fb0abca6c64540fff
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 3, Pp 100643- (2024)
Introduction: Biomarker testing in oncology is fundamental for targeted therapy use and clinical trial participation. Factors contributing to previously identified racial disparities in biomarker testing remain unclear. This study investigated biomar
Externí odkaz:
https://doaj.org/article/a8845350d9c14bc2864dbde968b3f501
Publikováno v:
Diagnostics, Vol 13, Iss 6, p 1117 (2023)
The treatment of non-small cell lung cancer has dramatically changed over the last decade through the use of targeted therapies and immunotherapies. Implementation of these treatment regimens relies on detailed knowledge regarding each tumor’s spec
Externí odkaz:
https://doaj.org/article/e204086347524669aec2ed886181f6fc
Autor:
Nickolas Stabellini, MS, Debora S. Bruno, MD, MS, Mantas Dmukauskas, PhD, Amie J. Barda, PhD, Lifen Cao, MD, PhD, John Shanahan, BA, Kristin Waite, PhD, Alberto J. Montero, MD, PhD, Jill S. Barnholtz-Sloan, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 4, Pp 100307- (2022)
Introduction: Lung cancer is the leading cause of cancer-related death and the second most often diagnosed malignancy worldwide. Males have higher incidence of lung cancer and higher mortality. It is hypothesized that the sex differences in survival
Externí odkaz:
https://doaj.org/article/71710e1ca9ad4463a192b5fb5795ebde
Publikováno v:
Case Reports in Oncology, Vol 12, Iss 1, Pp 164-170 (2019)
Pembrolizumab is a programmed death receptor-1 (PD-1) inhibitor that has been approved for treatment of a wide variety of malignancies. Immune-mediated colitis is a known but uncommon adverse effect of pembrolizumab. Symptoms of immune-mediated colit
Externí odkaz:
https://doaj.org/article/6e1afaac7e0c4cbc860943a70c5df228
Autor:
David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Gregory J. Riely, Jonathan Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, Miranda Hughes
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:340-350
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for management of disease in patients with NSCLC. These NCCN Guidelines Insights focus on neoadjuvant and adjuvant (also known as perioperative) systemic therapy opt
Autor:
Mitchell Machtay, Stanton L. Gerson, Monaliben Patel, David L. Bajor, Debora S. Bruno, Shufen Cao, Pingfu Fu, Shakun Malik, Nancy L. Oleinick, John J. Pink, Charles A. Kunos, Afshin Dowlati, Tithi Biswas
Purpose:TRC102, a small-molecule base-excision repair inhibitor, potentiates the cytotoxicity of pemetrexed and reverses resistance by binding to chemotherapy-induced abasic sites in DNA. We conducted a phase I clinical trial combining pemetrexed and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20ee52ebdeb49d0abe7e18d85aaed4c0
https://doi.org/10.1158/1078-0432.c.6531291.v1
https://doi.org/10.1158/1078-0432.c.6531291.v1
Autor:
Mitchell Machtay, Stanton L. Gerson, Monaliben Patel, David L. Bajor, Debora S. Bruno, Shufen Cao, Pingfu Fu, Shakun Malik, Nancy L. Oleinick, John J. Pink, Charles A. Kunos, Afshin Dowlati, Tithi Biswas
Supplementary Data from Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed–Platinum–Radiation in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer: Results of a Phase I Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4154f925bb072fc0960c03a8ac23962e
https://doi.org/10.1158/1078-0432.22483995
https://doi.org/10.1158/1078-0432.22483995
Autor:
Kai He, David Berz, Shirish M. Gadgeel, Wade T. Iams, Debora S. Bruno, Collin M. Blakely, Alexander I. Spira, Manish R. Patel, David M. Waterhouse, Donald A. Richards, Anthony Pham, Robert Jotte, David S. Hong, Edward B. Garon, Anne Traynor, Peter Olson, Lisa Latven, Xiaohong Yan, Ronald Shazer, Ticiana A. Leal
Publikováno v:
Journal of Thoracic Oncology.
Autor:
Pingfu Fu, Monaliben Patel, John J. Pink, Tithi Biswas, Mitchell Machtay, Shufen Cao, Charles A Kunos, Debora S. Bruno, Stanton L. Gerson, David L. Bajor, Nancy L. Oleinick, Shakun Malik, Afshin Dowlati
Publikováno v:
Clin Cancer Res
Purpose: TRC102, a small-molecule base-excision repair inhibitor, potentiates the cytotoxicity of pemetrexed and reverses resistance by binding to chemotherapy-induced abasic sites in DNA. We conducted a phase I clinical trial combining pemetrexed an